Overview

Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)

Status:
Not yet recruiting
Trial end date:
2025-07-30
Target enrollment:
Participant gender:
Summary
This is an escalation/expansion, open label, multicenter study to investigate the safety and the RP2D of the combination of iadademstat with gilteritinib in FLT3-mutated R/R AML.
Phase:
Phase 1
Details
Lead Sponsor:
Oryzon Genomics S.A.